Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis-Reference-Cited by-同舟云学术

Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis

Published:2015-12-24 Issue:1 Volume:59 Page:313-327
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Ruminski Peter G.,Massa Mark,Strohbach Joseph,Hanau Cathleen E.,Schmidt Michelle,Scholten Jeffrey A.,Fletcher Theresa R.,Hamper Bruce C.,Carroll Jeffery N.,Shieh Huey S.,Caspers Nicole,Collins Brandon,Grapperhaus Margaret,Palmquist Katherine E.,Collins Joe,Baldus John E.,Hitchcock Jeffrey,Kleine H. Peter,Rogers Michael D.,McDonald Joseph,Munie Grace E.,Messing Dean M.¹,Portolan Silvia¹,Whiteley Laurence O.²,Sunyer Teresa,Schnute Mark E.

Affiliation:

1. Pharmacokinetics, Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States

2. Drug Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.5b01434

Reference29 articles.

1. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II

2. The epidemiology of osteoarthritis